XNCR Quote, Financials, Valuation and Earnings

Catalyst Pharmaceuticals has a net margin of -147.92% compared to Xencor's net margin of 40.12%. Xencor's return on equity of -32.34% beat Catalyst Pharmaceuticals's return on equity of 29.43%.

Xencor has a consensus price target of $28.20, signalling upside risk potential of 206.86%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $34.29 which suggests that it could grow by 45.71%. Given that Xencor has higher upside potential than Catalyst Pharmaceuticals, analysts believe Xencor is more attractive than Catalyst Pharmaceuticals.

Xencor has a beta of 0.869, which suggesting that the stock is 13.145% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.721, suggesting its less volatile than the S&P 500 by 27.922%.

Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

Xencor quarterly revenues are $32.7M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $141.4M. Xencor's net income of -$48.4M is lower than Catalyst Pharmaceuticals's net income of $56.7M. Notably, Xencor's price-to-earnings ratio is -- while Catalyst Pharmaceuticals's PE ratio is 14.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 4.92x versus 5.54x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of -147.92% compared to Xencor's net margin of -486.44%. Xencor's return on equity of -32.34% beat Nektar Therapeutics's return on equity of -201.73%.

Xencor has a consensus price target of $28.20, signalling upside risk potential of 206.86%. On the other hand Nektar Therapeutics has an analysts' consensus of $4.92 which suggests that it could grow by 758.56%. Given that Nektar Therapeutics has higher upside potential than Xencor, analysts believe Nektar Therapeutics is more attractive than Xencor.

Xencor has a beta of 0.869, which suggesting that the stock is 13.145% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 0.552, suggesting its less volatile than the S&P 500 by 44.806%.

Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Xencor quarterly revenues are $32.7M, which are larger than Nektar Therapeutics quarterly revenues of $10.5M. Xencor's net income of -$48.4M is higher than Nektar Therapeutics's net income of -$50.9M. Notably, Xencor's price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 4.92x versus 1.38x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical has a net margin of -147.92% compared to Xencor's net margin of -108.46%. Xencor's return on equity of -32.34% beat Ultragenyx Pharmaceutical's return on equity of -205.06%.

Xencor has a consensus price target of $28.20, signalling upside risk potential of 206.86%. On the other hand Ultragenyx Pharmaceutical has an analysts' consensus of $89.84 which suggests that it could grow by 139.64%. Given that Xencor has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Xencor is more attractive than Ultragenyx Pharmaceutical.

Xencor has a beta of 0.869, which suggesting that the stock is 13.145% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical has a beta of 0.250, suggesting its less volatile than the S&P 500 by 75%.

Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical pays out -- of its earnings as a dividend.

Xencor quarterly revenues are $32.7M, which are smaller than Ultragenyx Pharmaceutical quarterly revenues of $139.3M. Xencor's net income of -$48.4M is higher than Ultragenyx Pharmaceutical's net income of -$151.1M. Notably, Xencor's price-to-earnings ratio is -- while Ultragenyx Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 4.92x versus 5.94x for Ultragenyx Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -147.92% compared to Xencor's net margin of 26.7%. Xencor's return on equity of -32.34% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Xencor has a consensus price target of $28.20, signalling upside risk potential of 206.86%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $727.21 which suggests that it could grow by 37.41%. Given that Xencor has higher upside potential than Regeneron Pharmaceuticals, analysts believe Xencor is more attractive than Regeneron Pharmaceuticals.

Xencor has a beta of 0.869, which suggesting that the stock is 13.145% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.309, suggesting its less volatile than the S&P 500 by 69.074%.

Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.33% to investors and pays a quarterly dividend of $0.88 per share. Xencor pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Xencor quarterly revenues are $32.7M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Xencor's net income of -$48.4M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Xencor's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 13.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 4.92x versus 4.29x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.